sci-news.jpeg

sci-news

shimin.jpeg

shimin

eppharmaline.gif

eppharmaline

findat.jpeg

findat

yakuzemi.png

yakuzemi

new-lifescience.gif

new-lifescience

biopharmaceuticals.gif

biopharmaceuticals

jssx36.png

jssx36

convention.jpeg

convention

jshp2022-thk.png

jshp2022-thk

jasdi24.png

jasdi24

General information

Announcements(0)

Greetings from Chair

Overview

Registration

General information 2

Abstract Submission (Oral/Poster Presentation)

Program

Sessions

Search presentations

pharm142_en.png

Change account information such as the email address and password on the account setting screen common to Confit.

Login required to view

Password required to view

Presentation Information

Session Details

A password that applicants have been notified of is required to view abstracts.<br>If you are a participant and need to confirm the password, please contact us by e-mail about which annual meeting you would like to know the password for to view abstracts.<br>We will reply after confirming that you were a participant.<br>Thank you for your understanding.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Program Type

Announcements

Profile management

Bookmark

Download PDF for print

Timetable

Monoclonal antibodies for cancer therapy: future perspective of multifunctional modality

The success of immune checkpoint therapy has revolutionized the field of cancer therapy and immunotherapy and is now an impregnable pillar in the field of therapeutics. However, positive responses are observed only in a minority of patients and tumor types, and several resistance mechanisms have been identified. The emerging focus in this area is on improving the response rate and overcoming resistance. To address this, combination therapies are currently being evaluated in ongoing clinical trials. Nanotechnology-based drug-delivery systems (nano DDS) are an important contribution to this area and to the future development of effective combination therapies via maximizing immune functional molecules and controlling the complicated antitumor immune responses. In this symposium, we focus on the role of nano DDS in cancer immunotherapy and the use of nano DDS technology in next-generation cancer immunotherapy. In addition, we introduce cancer immunotherapy, especially antibody drugs, in terms of regulatory issues. This symposium provides an opportunity to discuss cancer immunotherapy development based on nano-DDS, ranging from the basics to clinical applications.

Acceleration of cancer immunotherapy by nano-DDS

The 142nd Annual Meeting of the Pharmaceutical Society of Japan (Nagoya)

Presentation Information

[S19-2]Monoclonal antibodies for cancer therapy: future perspective of multifunctional modality

Password required to view